TrialThe oncologist2024

Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors.

Cheng Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.